Online citations, reference lists, and bibliographies.
← Back to Search

Hypothetical Model Of Dynamic Biomarkers Of The Alzheimer's Pathological Cascade

C. Jack, D. Knopman, W. Jagust, L. Shaw, P. Aisen, M. Weiner, R. Petersen, J. Trojanowski
Published 2010 · Psychology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
This paper references
Autopsy case report.
C. W. Chastain (1973)
10.1126/SCIENCE.462184
Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat.
W. Schwartz (1979)
10.1212/WNL.34.7.939
Clinical diagnosis of Alzheimer's disease
G. Mckhann (1984)
10.1002/ANA.410300410
Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
R. Terry (1991)
10.1212/WNL.42.1.183
MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease
C. Jack (1992)
10.1126/SCIENCE.8346443
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
E. Corder (1993)
10.1097/00005072-199409000-00002
Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease
A. Roses (1994)
10.1007/BF02815140
Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
K. Blennow (1995)
10.1002/ANA.410380414
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease
H. Arai (1995)
Tau in cerebrospinal fl uid: a potential diagnostic marker in Alzheimer's disease
H Arai (1995)
10.1111/jon199663156
Functional Imaging Predicts Cognitive Decline in Alzheimer's Disease
W. Jagust (1996)
10.1097/00001756-199712220-00022
The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease
T. Tapiola (1997)
10.1002/JMRI.1880070620
Brain atrophy progression measured from registered serial MRI: Validation and application to alzheimer's disease
Nick C Fox (1997)
10.1002/ANA.410420114
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
S. Minoshima (1997)
10.1002/ANA.410410106
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
T. Gómez-Isla (1997)
10.1016/S0197-4580(97)00056-0
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
H. Braak (1997)
10.1212/WNL.48.5.1297
Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia
J. Kaye (1997)
10.1016/S0197-4580(97)00047-X
Prevalence, Incidence and Duration of Braak’s Stages in the General Population: Can We Know?
C. Duyckaerts (1997)
brillary tangles in Alzheimer’s disease
DA Bennett (1997)
The level of cerebrospinal fl uid tau correlates with neurofi brillary tangles in Alzheimer ’ s disease
H Bian (1997)
The level of cerebrospinal fl uid tau correlates with neurofi brillary tangles in Alzheimer's disease
T Tapiola (1997)
10.1006/exnr.1998.6860
High Frequency of Apolipoprotein E ϵ4 Allele in Young Individuals with Very Mild Alzheimer's Disease-Related Neurofibrillary Changes
E. Ghebremedhin (1998)
In vivo MR spectroscopy of human dementia.
B. Ross (1998)
10.1002/ANA.410440226
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease
E. Reiman (1998)
10.1212/WNL.50.6.1585
Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease
V. Ibáñez (1998)
10.1016/S0306-4522(99)00476-5
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease
M. Bobinski (1999)
10.1212/WNL.52.7.1397
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
C.R. Jack (1999)
10.1016/S0140-6736(99)00496-1
Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease
Nick C Fox (1999)
10.1016/S0006-3223(99)00143-2
Longitudinal stability of CSF tau levels in Alzheimer patients
T. Sunderland (1999)
10.1212/WNL.52.8.1687
Correlation between rates of brain atrophy and cognitive decline in AD
Nick C Fox (1999)
10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease
J. Price (1999)
FDG PET imaging in patients with pathologically verified dementia.
J. Hoffman (2000)
FDG PET imaging in patients with pathologically verifi ed dementia
Jm Hoff Man (2000)
10.1016/S0197-4580(01)00230-5
Hippocampal formation glucose metabolism and volume losses in MCI and AD
S. Santi (2001)
10.1016/S0304-3940(00)01697-9
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
C. Hesse (2001)
10.1073/pnas.191044198
Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET)
M. D. de Leon (2001)
10.1097/00004647-200110000-00001
An Energy Budget for Signaling in the Grey Matter of the Brain
D. Attwell (2001)
10.1097/00001756-200210280-00022
Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment
G. Chételat (2002)
10.1126/SCIENCE.1072994
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
J. Hardy (2002)
10.1212/WNL.58.5.750
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia
C. Jack (2002)
10.1093/JNEN/62.11.1087
Neuropathology of Cognitively Normal Elderly
D. Knopman (2003)
10.1016/j.neuroimage.2003.07.002
Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons
A. Rocher (2003)
10.1001/ARCHNEUR.60.12.1696
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
C. Clark (2003)
10.1212/01.WNL.0000079053.77227.14
Changes in premorbid brain volume predict Alzheimer’s disease pathology
L.C. Silbert (2003)
10.1016/S0304-3940(02)01483-0
Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients
L. Wahlund (2003)
10.1212/01.WNL.0000055847.17752.E6
Mild cognitive impairment
G. Chételat (2003)
10.1016/S0140-6736(03)14469-8
Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study
D. Chan (2003)
10.1001/JAMA.290.12.1581
APOE genotype and cerebral blood flow in healthy young individuals.
N. Scarmeas (2003)
10.1073/pnas.2635903100
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
E. Reiman (2003)
10.1212/01.WNL.0000046581.81650.D0
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D. Strozyk (2003)
Cerebrospinal fl uid tau and beta-amyloid: how well do these biomarkers refl ect autopsy-confi rmed dementia diagnoses?
Cm Clark (2003)
Cerebrospinal fl uid tau and beta - amyloid : how well do these biomarkers refl ect autopsy - confi rmed dementia diagnoses ?
D Strozyk (2003)
10.1016/j.neurobiolaging.2004.02.010
Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer’s disease
W. Klein (2004)
10.1002/ana.20009
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
William E. Klunk (2004)
10.1212/01.WNL.0000115115.98960.37
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
M. Ingelsson (2004)
10.1111/j.1365-2796.2004.01388.x
Mild cognitive impairment as a diagnostic entity
R. Petersen (2004)
10.1001/ARCHNEUR.61.3.378
Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function.
D. Bennett (2004)
10.1212/01.WNL.0000110315.26026.EF
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
C. Jack (2004)
10.1007/BF00308809
Neuropathological stageing of Alzheimer-related changes
H. Braak (2004)
ed amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease
S Oddo (2004)
Small assemblies of unmodifi ed amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease
Wl Klein (2004)
10.1002/ana.20477
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease
M. Grossman (2005)
10.1523/JNEUROSCI.2177-05.2005
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory
R. Buckner (2005)
10.1177/0891988705281872
Recent Clinical-Pathologic Research on the Causes of Dementia in Late Life: Update From the Honolulu-Asia Aging Study
L. White (2005)
Cerebrospinal fl uid profi le in frontotemporal dementia and Alzheimer's disease
M Grossman (2005)
Cerebrospinal fl uid profi le in frontotemporal dementia and Alzheimer ’ s disease
C Ballatore (2005)
10.1212/01.wnl.0000242732.06714.0f
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury
M. Öst (2006)
10.1212/01.wnl.0000228230.26044.a4
[11C]PIB in a nondemented population
M. Mintun (2006)
10.1097/01.wad.0000213815.20177.19
Cognitive Reserve and Alzheimer Disease
Y. Stern (2006)
10.1074/jbc.M507892200
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
S. Oddo (2006)
10.1093/BRAIN/AWL178
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
H. Engler (2006)
10.1093/BRAIN/AWL269
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
K. Buerger (2006)
10.1016/S1474-4422(06)70550-6
Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study
B. Ridha (2006)
10.1002/ana.20799
Brain imaging evidence of preclinical Alzheimer's disease in normal aging
W. Jagust (2006)
10.1001/ARCHNEUR.63.7.936
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition.
E. Peskind (2006)
10.1002/ana.20730
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
Anne M. Fagan (2006)
brillary pathology in Alzheimer’s disease
LM Shaw (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fl uid Aβ 42 in humans
WJ Jagust (2006)
Temporal profi le of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology
S Oddo (2006)
Alzheimer Dis Assoc Disord
(2006)
amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology
T Gomez-Isla (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fl uid Aβ 42 in humans
Am Fagan (2006)
10.1159/000105017
Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly
E. Stomrud (2007)
10.1212/01.wnl.0000271375.37131.04
Longitudinal changes of CSF biomarkers in memory clinic patients
F. Bouwman (2007)
10.1212/01.wnl.0000286944.22262.ff
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI
M. Ewers (2007)
10.1212/01.wnl.0000271090.28148.24
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
J. Schneider (2007)
10.1038/nrd2176
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
L. Shaw (2007)
10.1001/ARCHNEUR.64.3.431
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
B. Bacskai (2007)
10.1093/BRAIN/AWM112
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.
J. Whitwell (2007)
10.1038/nrn2194
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
C. Ballatore (2007)
10.1212/01.wnl.0000267428.62582.aa
CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment
G. Li (2007)
10.1136/jnnp.2006.100529
Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women
D. Gustafson (2006)
10.1001/ARCHNEUR.64.3.NOC60123
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
A. Fagan (2007)
10.1016/S1474-4422(07)70178-3
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
B. Dubois (2007)
10.1212/01.wnl.0000244749.20056.d4
Amyloid, hypometabolism, and cognition in Alzheimer disease
P. Edison (2007)
10.1212/01.wnl.0000269790.05105.16
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
W. Jagust (2007)
beta-amyloid 1-42 concentration may predict cognitive decline in older women
E Stomrud (2007)
10.1093/brain/awm336
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
C. Jack (2008)
10.1001/archneur.65.11.1509
Frequent amyloid deposition without significant cognitive impairment among the elderly.
H. Aizenstein (2008)
10.1093/brain/awn016
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
M. Ikonomovic (2008)
10.1002/ana.21223
β‐amyloid burden is not associated with rates of brain atrophy
K. Josephs (2008)
10.1016/j.nbd.2008.08.001
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study
P. Edison (2008)
10.1212/01.wnl.0000318046.06992.24
IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA
G. Linazasoro (2008)
10.1016/S0140-6736(08)61075-2
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
C. Holmes (2008)
10.1212/01.wnl.0000324924.91351.7d
MRI correlates of neurofibrillary tangle pathology at autopsy
J. Whitwell (2008)
10.1212/01.wnl.0000311445.21321.fc
CSF biomarkers in frontotemporal lobar degeneration with known pathology
H. Bian (2008)
10.1016/j.neurobiolaging.2006.11.018
CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
N. Schoonenboom (2008)
Core candidate neurochemical and imaging biomarkers of Alzheimer’s disease
H Hampel (2008)
¹¹C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment
Cr Jack (2008)
10.1001/jama.2009.1064
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
N. Mattsson (2009)
10.1001/archneurol.2009.59
Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
E. Petrie (2009)
10.1016/j.neurobiolaging.2008.02.007
CSF biomarker levels in early and late onset Alzheimer's disease
F. Bouwman (2009)
10.1038/NG.440
Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease
D. Harold (2009)
10.1016/j.neuron.2009.07.003
Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia
R. Sperling (2009)
10.1093/brain/awp062
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
C. Jack (2009)
10.1038/ng.440
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes
D. Harold (2009)
10.1038/NG.439
Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer
Xifeng Wu (2009)
10.1523/JNEUROSCI.5062-08.2009
Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease
R. Buckner (2009)
10.1212/WNL.0b013e3181bc010c
Relationships between biomarkers in aging and dementia
W. Jagust (2009)
10.1002/ana.21610
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
L. Shaw (2009)
10.1002/ana.21559
Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly
A. Fagan (2009)
10.1007/s00401-009-0583-3
Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease
R. Rosen (2010)
10.1073/pnas.0900345106
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease
E. Reiman (2009)
10.1093/brain/awn320
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects.
E. Mormino (2009)
10.1038/ng.439
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
J. Lambert (2009)
10.1212/WNL.0b013e3181a2e8d0
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
A. Drzezga (2009)
10.1016/S1474-4422(09)70139-5
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
P. Visser (2009)
10.1056/NEJMoa0806142
Age, neuropathology, and dementia.
G. Savva (2009)
10.1212/WNL.0b013e3181af79e5
MRI and CSF biomarkers in normal, MCI, and AD subjects
P. Vemuri (2009)
10.3174/ajnr.A1357
Fluorodeoxyglucose–Positron-Emission Tomography, Single-Photon Emission Tomography, and Structural MR Imaging for Prediction of Rapid Conversion to Alzheimer Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis
Y. Yuan (2008)
10.1212/WNL.0b013e3181a2e896
In vivo mapping of amyloid toxicity in Alzheimer disease
G. Frisoni (2009)
10.1016/j.biopsych.2009.01.027
Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
T. Grimmer (2009)
10.2967/jnumed.109.064360
Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding
N. Tolboom (2009)
Defi cient high - affi nity binding of Pittsburgh compound B in a case of Alzheimer ’ s disease
CM Clark (2009)
Genome - wide association study identifi es variants at CLU and PICALM associated with Alzheimer ’ s disease
D Harold (2009)
Genome-wide association study identifi es variants at CLU and CR1 associated with Alzheimer's disease
Jc Lambert (2009)
Relationship of cerebrospinal fl uid markers to 1 1 CPiB and 1 8F - FDDNP binding
K Buerger (2009)
es variants at CLU and PICALM associated with Alzheimer’s disease
JC Lambert (2009)
Acta Neuropathol
(2009)
Relationship of cerebrospinal fl uid markers to ¹¹C-PiB and ¹⁸F-FDDNP binding
N Tolboom (2009)
es variants at CLU and PICALM associated with Alzheimer’s disease
JC Lambert (2009)
10.1016/S1474-4422(09)70330-8
Alzheimer's disease: progress in prediction
R. Petersen (2010)
10.1016/j.neurobiolaging.2008.06.016
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study
J. Sluimer (2010)
10.1111/j.1750-3639.2008.00244.x
Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons
P. Nelson (2010)
Defi cient high-affi nity binding of Pittsburgh compound B in a case of Alzheimer's disease
Rf Rosen



This paper is referenced by
10.1016/b978-0-12-821334-6.00004-1
Using big data methods to understand Alzheimer’s disease
Samuel L. Warren (2022)
10.1016/j.bbr.2021.113589
Basolateral amygdala stimulation plus water maze training restore dentate gyrus LTP and improve spatial learning and memory
D. Mercerón-Martínez (2021)
10.1071/CH21007
Imaging Cannabinoid Receptors: A Brief Collection of Covalent and Fluorescent Probes for CB1 and CB2 Receptors
Alexander J. Hamilton (2021)
10.1016/s1634-7072(21)45320-1
Diagnosi clinicolaboratoristica della malattia di Alzheimer
J. Lagarde (2021)
10.1016/j.nicl.2021.102799
Apolipoprotein E allele 4 effects on Single-Subject Gray Matter Networks in Mild Cognitive Impairment
Gretel Sanabria-Diaz (2021)
10.3389/fnagi.2021.593898
Gray Matter Deterioration Pattern During Alzheimer's Disease Progression: A Regions-of-Interest Based Surface Morphometry Study
Z. Wu (2021)
10.1002/alz.12313
Ophthalmic conditions associated with dementia risk: The Cardiovascular Health Study
Phillip H. Hwang (2021)
10.3390/ijms22189734
Should We Open Fire on Microglia? Depletion Models as Tools to Elucidate Microglial Role in Health and Alzheimer’s Disease
Carmen Romero-Molina (2021)
10.3233/jad-210064
PET Imaging of Tau Pathology and Amyloid-β, and MRI for Alzheimer's Disease Feature Fusion and Multimodal Classification.
Mehdi Shojaie (2021)
10.3390/cells10113064
DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer’s, Related Tauopathies and Genetic Tauopathies
(2021)
10.1007/s00259-021-05230-5
PET imaging of neural activity, β-amyloid, and tau in normal brain aging
Kai Zhang (2021)
10.3389/fneur.2021.699014
Brain Network Integrity Changes in Subjective Cognitive Decline: A Possible Physiological Biomarker of Dementia
Hilla Fogel (2021)
Orthogonalized Kernel Debiased Machine Learning for Multimodal Data Analysis
(2021)
10.36150/2499-6564-n327
Biological diagnosis of Alzheimer’s disease and the issue of stigma
Flavio Ronchetto (2021)
10.3390/genes12081247
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
L. Ibañez (2021)
10.1016/j.neuroimage.2021.118553
Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data
Christina B. Young (2021)
10.1111/acel.13358
Platelet biomarkers for a descending cognitive function: A proteomic approach
Haitao Yu (2021)
10.1016/j.jns.2020.117270
Comparing fluid biomarkers of Alzheimer's disease between African American or Black African and white groups: A systematic review and meta-analysis
Aiysha Chaudhry (2020)
10.1016/B978-0-12-818000-6.00039-1
Training the functionality of daily life. A new neuroscientific paradigm of cognitive training
C. Requena (2021)
10.3389/fdata.2021.676168
Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort
J. Howlett (2021)
10.1186/s13024-021-00467-y
The informed road map to prevention of Alzheimer Disease: A call to arms
E. McDade (2021)
10.1093/braincomms/fcab140
Machine learning identifies novel markers predicting functional decline in older adults
K. Valerio (2021)
10.1039/d1md00030f
Anti-amyloidogenic indolizino[3,2-c]quinolines as imaging probes differentiating dense-core, diffuse, and coronal plaques of amyloid-β.
(2021)
10.3389/fneur.2021.651388
The Effect of the APOE-ε4 Allele on the Cholinergic Circuitry for Subjects With Different Levels of Cognitive Impairment
Ying-Liang Larry Lai (2021)
10.1101/2021.08.26.21262325
Predicting brain amyloid-β PET phenotypes with graph convolutional networks based on functional MRI and multi-level functional connectivity
C. Li (2021)
10.1007/s00726-020-02928-y
Serum amino acid profiles in patients with mild cognitive impairment and in patients with mild dementia or moderate dementia
Edyta Socha (2021)
10.1002/alz.12305
Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias
E. Disbrow (2021)
10.3233/jad-215046
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?
Ebba Gløersen Müller (2021)
Orthogonal Statistical Inference for Multimodal Data Analysis
(2021)
10.1155/2021/9121770
Automatic Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment Based on CNN + SVM Networks with End-to-End Training
Zhe Huang (2021)
10.1111/ene.14919
A disease‐specific metabolic imaging marker for diagnosis and progression evaluation of semantic variant primary progressive aphasia
Jiaying Lu (2021)
10.3389/fnagi.2021.607858
Machine Learning Profiling of Alzheimer's Disease Patients Based on Current Cerebrospinal Fluid Markers and Iron Content in Biofluids
Eleonora Ficiarà (2021)
See more
Semantic Scholar Logo Some data provided by SemanticScholar